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Abstract
Prostate epithelial cells control the potency and availability of androgen hormones in part by 
inactivation and elimination. UDP-glucose dehydrogenase (UGDH) catalyzes the NAD+-
dependent oxidation of UDP-glucose to UDP-glucuronate, an essential precursor for androgen 
inactivation by the prostate glucuronidation enzymes UGT2B15 and UGT2B17. UGDH 
expression is androgen stimulated, which increases the production of UDP-glucuronate, and fuels 
UGT-catalyzed glucuronidation. In this study, we compared the glucuronidation potential and its 
impact on androgen-mediated gene expression in an isogenic LNCaP model for androgen 
dependent versus castration resistant prostate cancer. Despite significantly lower androgen-
glucuronide output, LNCaP 81 castration resistant tumor cells expressed higher levels of UGDH, 
UGT2B15, and UGT2B17. However, the magnitude of androgen-activated UGDH and PSA 
expression, as well as the AR-dependent repression of UGT2B15 and UGT2B17, was blunted 
several-fold in these cells. Consistent with these results, the ligand-activated binding of AR to the 
PSA promoter and subsequent transcriptional activation were also significantly reduced in 
castration resistant cells. Analysis of the UDP-sugar pools and flux through pathways downstream 
of UDP-glucuronate production revealed that these glucuronidation precursor metabolites were 
channeled through proteoglycan and glycosaminoglycan biosynthetic pathways, leading to 
increased surface expression of Notch 1. Knockdown of UGDH diminished Notch1 and increased 
glucuronide output. Overall, these results support a model in which the aberrant partitioning of 
UDP-glucuronate and other UDP-sugars into alternative pathways during androgen deprivation 
contributes to the loss of prostate tumor cell androgen sensitivity by promoting altered cell surface 
proteoglycan expression.
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 Introduction
Prostate cancer is the most commonly diagnosed cancer in men [1]. Locally advanced cancer 
that is present at first diagnosis is often inoperable and treated by androgen deprivation 
therapy [2]. Most tumors respond initially, but recurrence is a serious clinical problem 
because tumor cells that resume growth despite low circulating androgen are highly 
aggressive [3, 4]. A major cause of mortality in prostate cancer is castration resistant 
recurrence [5, 6, 2], but the underlying molecular mechanisms are not yet fully understood 
and are therefore an area of intense research focus. It is well accepted that tumor cells can 
acquire the ability to synthesize androgens locally [7] or develop aberrant androgen receptor 
(AR) functions through post-transcriptional and post-translational modifications that 
eliminate the need for exogenous androgen [8, 9]. However, less is known about the impacts 
of androgen elimination pathways on castration resistant progression.
Excess androgen is normally managed by the glucuronidation pathway, in which steroids or 
other lipophiles are chemically inactivated and solubilized by conjugation to glucuronate 
moieties. UDP-glucuronosyltransferase (UGT) enzymes are expressed in hormone-sensitive 
target tissues and catalyze the esterification of a steroid hydroxyl to the anomeric carbon of 
UDP-glucuronate (UDP-glcA), yielding the androgen-glucuronide with UDP as a leaving 
group [10]. The net effect is to maintain levels of critical lipophilic hormones in the 
concentration windows at which they are most effective in engaging their receptors. Prostate 
epithelial cells express two UGT isoforms, UGT2B15 and UGT2B17 [11]. Cell culture 
experiments show that expression of these 95% identical isoforms is androgen repressed and 
their overexpression reduces the proliferation rate of cells by increasing inactivation of 
androgens [12–15]. Importantly, polymorphisms in both genes have been identified and 
correlated as genetic risk factors for prostate cancer [16, 17]. In addition, comparison of 
castration resistant murine and human prostate tumor metastases to primary tumors revealed 
increased expression of UGT2B17 in conjunction with increases in several androgen 
biosynthetic enzymes [18].
UDP-glucose dehydrogenase (UGDH) is a unique, essential enzyme that catalyzes oxidation 
of UDP-glucose to UDP-glcA, which is the required precursor for glucuronidation. Many 
tissues express UGDH, but strong expression is specific to liver and prostate [19], both 
tissues that actively demand glucuronate conjugation to facilitate hormone excretion. We 
previously showed that stimulating UGDH expression and consequently increasing UDP-
glcA cofactor availability can drive UGT-catalyzed glucuronidation by mass action in 
androgen dependent prostate tumor cells [20]. We have also found that UGDH expression is 
significantly elevated in epithelial cells of cancerous prostate acini relative to those of both 
normal prostate or those of normal appearing acini at the tumor/normal interface in biopsied 
samples [21].
In the current study, our goal was to characterize the function of the glucuronidation 
pathway during loss of androgen dependence, and determine the effects of altered androgen 
availability on the component enzymes and metabolite intermediates. We used an isogenic 
cell culture model of androgen dependent and castration resistant prostate cancer, LNCaP 33 
and LNCaP 81. LNCaP 81 was derived from LNCaP 33 by long-term passage in androgen-
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containing culture conditions to achieve a cell population that remained androgen responsive 
but was no longer androgen dependent [22]. We tested the effect of short-term and 
prolonged androgen deprivation on AR-dependent gene expression and activity of UGDH, 
UGT2B15, UGT2B17, and the UDP-sugar metabolites. We found that androgen sensitive 
LNCaP 33 cells retained greater dynamic potential for AR-mediated gene expression and 
androgen-glucuronide secretion, while the LNCaP 81 counterparts partitioned UDP-glcA 
into increased synthesis of glycosaminoglycans. We confirmed these properties in 22Rv1 
cells, which are also a model for castration resistant prostate cancer. In addition, we reduced 
UDP-glcA by knocking down UGDH, which resulted in diminished proteoglycan 
production and increased androgen glucuronide output. These results are consistent with a 
model in which the altered flux of UDP-sugar intermediates through multiple downstream 
pathways blunts the function of the glucuronidation pathway and promotes intracellular 
androgen accumulation to sustain cellular proliferation in the absence of exogenous steroids.
 Materials and Methods
 Reagents
All reagents were obtained from Fisher Scientific (Pittsburgh, PA) except where indicated. 
5-α-dihydrotestosterone (DHT) and DHT-glucuronide were from Sigma (St. Louis, MO). 
Charcoal stripped FBS was from Hyclone (Logan, UT). Antibodies were purchased and used 
as follows: polyclonal rabbit anti-human PSA (DakoCytomation, Glostrup, Denmark, 
1:1500 dilution); mouse monoclonal anti-human β-tubulin (Sigma, 1:750,000); IRDye 800 
conjugated anti-rabbit IgG (Rockland, Gilberstville, PA, 1:5000); IRDye 680 conjugated 
goat anti-mouse IgG (LI-COR Biosciences, Lincoln, NE, 1:5000); rabbit polyclonal anti-
human UGT2B17 (1:100) and rabbit polyclonal anti-human HSD17B3 (GeneTex, Irvine, 
CA, 1:500); mouse monoclonal anti-human AR (Santa Cruz Biotechnology, Inc, Dallas, TX, 
1:500); rabbit monoclonal anti-human Notch 1 (Cell Signaling Technology, Danvers, MA, 
1:1000); mouse monoclonal anti-human HSD3B1 (1:100) and rabbit monoclonal anti-human 
ARv7 (Abcam, Cambridge, MA, 1:1000). Rabbit polyclonal anti-human UXS1 was raised 
against purified recombinant human UXS1, residues 85–420 (Pocono Rabbit Farms). The 
UXS1 expression construct was a gift from Nicola Burgess-Brown: Addgene plasmid # 
39162.
 Cell culture and selection of stable lines
LNCaP (denoted LNCaP 33 herein), 22Rv1, and PC3 human prostate adenocarcinoma cells 
were purchased from American Type Culture Collection (Manassas, VA), and maintained in 
culture for a maximum of ten passages after thaw. LNCaP 81 androgen independent cells 
were kindly provided by Dr. Ming-Fong Lin ([23] University of Nebraska Medical Center, 
Omaha, NE). For standard culture, PC3 was maintained in MEM supplemented with 10% 
FBS, non-essential amino acids, and sodium pyruvate; LNCaP and 22Rv1 lines were 
maintained in RPMI-1640 supplemented with 10% FBS, all as recommended by the vendor. 
To generate UGDH knockdown lines, LNCaP 33 cells were transfected with plasmids 
encoding shRNA targeted to UGDH or a scrambled non-targeting control (UGDH shRNA-
pGFP-V-RS #TG334012 and 29-mer oligo-pGFP-V-RS #TR30008, respectively, from 
Origene Technologies, Rockville, MD). Stable integration of the shRNA plasmids was 
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achieved by clonal selection in RPMI-1640 with 10% FBS and 1 μg/ml puromycin. Once 
selected, clones were maintained in the same medium containing 0.5 μg/ml of puromycin. 
Two clones of each were chosen for full characterization. Clones designated KD1 and KD2 
had >70% reduced UGDH protein expression relative to the two control clones designated 
C1 and C2 with UGDH expression identical to the parental line.
 Androgen stimulation
For short-term comparison of androgen response, LNCaP cells were subcultured to 50% 
confluence in phenol red-free RPMI-1640 supplemented with 1% charcoal stripped FBS 
(CS-FBS) for 48 h (androgen-depleted conditions). DHT was serially diluted into media 
from concentrated stocks solubilized in ethanol as a vehicle. Androgen-depleted media were 
replaced with media containing the indicated concentration of DHT for 48 h, and harvested 
for analysis. For long-term selection, cells were grown for 10 days in phenol red-free 
RPMI-1640 media containing 5% CS-FBS and 0 (vehicle), 0.1, 1, or 10 nM DHT. Media 
were renewed every two days. Following selection, cells were either maintained in these 
conditions, or subjected to 48 h in androgen-depleted media followed by 24–48 h 
stimulation with 10 nM DHT to quantify the magnitude of the androgen-stimulatable 
response.
 Western analysis
Cells were scraped into cold PBS following treatments, pelleted by centrifugation, and lysed 
in 1x RIPA buffer with protease inhibitor cocktail. Protein was quantified by Bradford assay 
and equivalent amounts of total protein were analyzed. UGDH (rabbit polyclonal anti-
human UGDH, 1:5000, [20]), AR, PSA, and β-tubulin were probed simultaneously in cell 
lysates. UGT2B17, UXS1, Notch 1, ARv7, HSD3B1, and HSD17B3 were each probed 
separately with β-tubulin on identical blots. Following secondary incubation, protein 
expression was quantified by fluorescence emission using the Odyssey Infrared Imaging 
System (LI-COR Biosciences, Lincoln, NE). Signals for each wavelength were analyzed in 
red (700 nm, tubulin and HSD3B1) and green (800 nm, all other targets), to normalize 
protein expression. Statistical significance was assessed by Student’s t-test. Each 
densitometric analysis is plotted for three technical replicates of a representative experiment 
that was repeated at least three times.
 Detection of UDP-glucuronosyltransferase mRNA expression
Total RNA was isolated from LNCaP 33 and 81 cells that had been cultured in different 
concentrations of androgen for 3–10 days and then treated with vehicle or 10 nM DHT for 
another 48 hrs. Equivalent amounts of total RNA were reverse transcribed; the UGT2B15 
and UGT2B17 coding sequences were amplified by PCR as previously published [20].
 Quantification of UDP-sugars and androgen glucuronide conjugates
Lysates from the indicated lines and treatments were extracted with butanol-saturated 
concentrated formic acid and analyzed for UDP-sugar content by liquid chromatography and 
mass spectrometry (LC-MS) according to published methods [24, 25]. Conditioned media 
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from androgen treated cell cultures were ethanol extracted for glucuronide analysis by LC-
MS/MS, also as published [20]. Statistical significance was assessed by Student’s t-test.
 Chromatin immunoprecipitation
LNCaP 33 and 81 were selected in DHT for 48 h or for 10 days. Media were removed and 
replaced with media containing vehicle or 10 nM DHT for 16 h prior to ChIP assay. After 
AR immunoprecipitation, qPCR was done using primers for the PSA enhancer element, 
PSA basal promoter (negative control) and actin (normalization control)[26]. AR bound to 
the PSA enhancer was plotted as % input (fraction of total AR immunoprecipitated DNA 
that was amplified by gene-specific primers) from a single assay done in triplicate that is 
representative of at least three separate selection trials per condition. Amplification of DNA 
from the basal promoter was confirmed to be <0.02% as expected for all conditions (not 
shown).
 Luciferase reporter assay
LNCaP 33 and 81 cells were grown in RPMI-1640 media containing 5% CS-FBS. After 10 
days of selection with 0, 0.1, 1, 10 nM of DHT, cells were transfected with pGL3-basic-Luc 
+ pRL-SV40 Renilla plasmids, or pGL3-PSA-Luc + pRL-SV40 Renilla plasmids. 24 hrs 
after transfection, cells were treated with vehicle or 10 nM DHT. After another 24 hrs, cells 
were harvested for luciferase assay using the Promega Dual Luciferase kit according to 
manufacturer instructions. Each experiment was done in triplicate wells and luciferase 
activities were normalized.
 Results
 Androgen dependent LNCaP cells have lower levels of glucuronidation enzymes and 
greater dynamic range in AR-mediated gene expression
We previously showed that UGDH was an androgen-stimulated gene, and that its elevation 
by DHT administration produced up to 6-fold more DHT-glucuronide secretion by LNCaP 
33 compared to LNCaP 81 cells [20], which model the androgen dependent versus castration 
resistant states of prostate cancer, respectively. To examine the impact of castration 
resistance on the glucuronidation pathway and AR-mediated gene expression, we exposed 
LNCaP 33 and 81 cells to two days of androgen-deficient media followed by an additional 
two days of vehicle (0 nM) or the indicated concentrations of DHT. As expected, UGDH 
expression was diminished in LNCaP 33 cells in the absence of DHT and restimulated at 
physiological doses (1 nM and 10 nM DHT, Fig 1A). UGDH levels were higher at all DHT 
doses in LNCaP 81 cells, and were not altered by androgen withdrawal. Also as expected, 
PSA expression was virtually absent in both lines without DHT, and restimulated expression 
was >10-fold higher in androgen sensitive LNCaP 33 cells (Fig 1B). AR expression, which 
is modestly suppressed by DHT, was ≈30% lower in LNCaP 81 cells than in 33 cells (Fig 
1C). UGT2B17 expression was upregulated in the absence of DHT in both LNCaP 33 and 
81 cells, but while the levels were potently suppressed by DHT in a dose dependent manner 
in LNCaP 33 cells, DHT treatment did not significantly reduce the elevated expression in 
LNCaP 81 cells (Fig 1D). Similar results were obtained using 22Rv1 cells, which express 
wild-type AR and are mildly androgen responsive but not androgen dependent (Fig S1A–
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S1D). In these cells, UGDH and UGT2B17 were also elevated, while PSA and AR 
expression were reduced, and levels were not altered by DHT. PC3 cells, which lack AR 
expression, also did not have PSA, appreciable levels of UGT2B17, or DHT-sensitive 
UGDH upregulation (Fig S1A–S1D). Collectively, these results show that the magnitude of 
both AR-mediated activation and repression was significantly reduced in the castration 
resistant state. Moreover, despite reduced DHT-glucuronide secretion, LNCaP 81 cells had 
elevated expression of the glucuronidation pathway enzymes UGDH and UGT2B17.
 Prolonged androgen depletion leads to dose dependent decreases in basal and 
androgen-stimulated gene expression
Increased UDP-glcA production by UGDH can drive androgen inactivation and thereby 
modify tumor cell growth in androgen responsive cells. If UGDH is a causative factor in 
these phenomena, its expression levels should be influenced by prolonged exposure to 
different DHT concentrations and translate to direct effects on AR-mediated gene 
expression. To test this, we selected LNCaP 33 and 81 cells for 10 days in androgen free 
media that were supplemented with 10-fold decrements of DHT from 10 nM to 0 nM 
(vehicle). We then examined the effects of selection on gene expression and AR 
transcriptional activity in the unstimulated and androgen treated states, to observe both basal 
impact and changes in responsiveness to hormones.
After selection for 10 days in androgen free media, UGDH basal expression in LNCaP 33 
cells was significantly reduced and could be stimulated 3.5-fold by re-introduction of DHT, 
while UGDH levels did not change in LNCaP 81 cells (Fig 2A shows relative stimulation). 
The drop in basal UGDH expression specifically in LNCaP 33 cells suggests that the 
provision of androgen from extracellular sources is necessary to sustain high levels of 
UGDH protein in these cells. Selection in the lowest concentration of androgen (0.1 nM) 
preserved UGDH expression such that only ≈1.6-fold stimulation was observed upon 
restoration of DHT (Fig 2A). In 1 nM or 10 nM conditions, no loss of UGDH expression 
was observed and no further stimulation occurred. That is, basal and stimulated UGDH 
expression was the same in LNCaP 33 and 81 cells that were selected in at least 1 nM DHT 
(Fig 2A). Thus, 1–10 nM DHT treatment appeared to be both necessary and sufficient to 
maintain UGDH expression in androgen sensitive cells. However, it is notable that this level 
of regulation was lost in cells that do not respond to exogenous DHT. We reprobed these 
western blots for PSA and for AR expression (Fig 2B). Similar dose dependent loss of 
expression was observed for PSA in both LNCaP 33 and 81 cells after selection, though as 
in the short-term treatments, PSA expression at all levels was significantly lower in LNCaP 
81 than in LNCaP 33. Expression of AR protein was not altered by selection.
 Extended androgen depletion elevates expression of UGT2B17 and reduces sensitivity 
of UGT2B15 and UGT2B17 to DHT suppression
AR has been shown to mediate DHT-induced suppression of UGT isoforms UGT2B15 and 
UGT2B17 in dose dependent fashion within a 24-hour time period [27]. Since mass action 
glucuronidation driven by UGDH requires UGT activity, we next quantified effects of 
differential androgen selection on basal and DHT-suppressible UGT expression. LNCaP 33 
and 81 cells were cultured in androgen depleted media for ten days and expression was 
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compared by qRT-PCR at an early time point (three days) and at endpoint. Selection for 10 
days modestly elevated expression of UGT2B15 in both LNCaP 33 and 81 cells relative to 
the 3-day time point, but UGT2B17 expression was ≈5-fold and ≈3.5-fold increased in 
LNCaP 33 and 81 cells, respectively (Fig 3A). It should be noted that although levels are 
normalized to emphasize pairwise fold comparison in the figure, expression of both 
isozymes was significantly higher in LNCaP 81 cells than in LNCaP 33 cells at three days. 
This finding is consistent with the short-term results in Figure 1, and suggests there is a loss 
of ligand-dependent AR activity at the UGT promoters.
We next selected LNCaP 33 and 81 cells in androgen decrements for 10 days, followed by a 
24 hour treatment with vehicle or DHT, and evaluated UGT2B15 and UGT2B17 expression 
by qRT-PCR (Fig 3B and 3C). Expression was normalized to its respective level at 0 nM 
DHT in the untreated samples. The expression of both UGT isozymes was 3–20-fold higher 
in LNCaP 81 than in 33 cells. In both lines, the degree to which DHT suppressed either 
isozyme was significantly reduced when cells were selected in the complete absence of 
DHT. In LNCaP 33 cells (Fig 3B and 3C), both UGT2B15 and UGT2B17 were sensitive to 
suppression by DHT treatment in all doses. UGT2B15 basal expression was relatively stable 
at all selection doses and suppressed by addition of 10 nM DHT as expected (Fig 3B, left 
panel). Inhibition of basal UGT2B17 expression in LNCaP 33 cells was ≈65% at 0.1 nM 
DHT selection and further suppressed (≈90%) at higher doses (Fig 3C, left panel). Upon 24-
hour treatment with DHT, expression was diminished by 55% if cells were selected in the 
complete absence of DHT, but up to >95% for all selection doses. Such strong regulation 
was not observed for the LNCaP 81 cells, though selection in DHT reduced UGT2B17 basal 
and stimulated levels by ≈50%. Thus, selection conditions profoundly impact regulation of 
UGT in prostate cells.
 Androgen deficient selection impacts ligand dependent AR binding and transcriptional 
activation of the PSA promoter/enhancer
Since AR regulates PSA expression, the lack of correlation between AR protein and 
restimulation of PSA after selection suggested an impact of selection on AR activity. To 
examine this, we used chromatin immunoprecipitation (ChIP) to quantify AR bound to the 
PSA androgen response element as previously described [28]. Cells were selected in 
decreasing androgen as indicated in the legend for a 10-day period and assayed by ChIP 
after a 16 hour treatment with or without 10 nM DHT (Fig 4A). As a positive control, results 
of the 10-day selection were compared to cell cultures selected for only 48 h before final 
DHT treatment, which were the conditions used in prior experiments [20]. Basal AR bound 
to the PSA enhancer was minimal in both cell lines whether cells were selected for 48 h or 
10 days unless first treated with DHT (Fig 4A, “DHT in ChIP”: 0 nM illustrates basal AR 
bound, 10 nM DHT added illustrates ligand-activated AR bound, indicated on the x-axis). In 
LNCaP 33 cells, presence of DHT in the selection media increased AR occupancy at the 
PSA enhancer in a dose dependent manner. Prolonged selection in low or no androgen 
strongly reduced the level of AR that could be stimulated to bind the PSA enhancer upon 
subsequent 10 nM DHT addition, relative to the 48 h treatment. In LNCaP 81 cells, less AR 
was bound to the PSA enhancer at all doses, which was only partially attributable to the 
reduced expression of AR in those cells, and DHT addition also did not stimulate 
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appreciable AR binding. To examine AR transcriptional activation, we used a luciferase 
reporter driven by the PSA promoter. Cells selected for 10 days in the indicated DHT 
concentrations were transfected for 24 h with the PSA-luciferase reporter or vector control, 
then stimulated for 24 h with DHT before harvesting and assaying luciferase activity (Fig 
4B). As observed in the ChIP assay, selection in decreasing androgen reduced the magnitude 
of reporter expression upon DHT stimulation, specifically in LNCaP 33 cells. These results 
are consistent with dose-dependent loss of AR promoter binding and transcriptional activity 
after prolonged low androgen selection.
To relate loss of AR function in LNCaP 81 cells to the overall status of glucuronidation 
pathway function, we quantified downstream metabolites and expression levels of gene 
products dependent on those metabolites. Figure 5A illustrates the three direct fates of UDP-
glucuronate in prostate tumor cells: (1) hyaluronan synthase (HAS) enzymes alternately 
polymerize glucuronate and N-acetylglucosamine using the UDP-esterified precursors; (2) 
UGT enzymes produce androgen-glucuronides including conjugates of testosterone, DHT, 
or androstanediol; (3) UDP-xylose synthase 1 (UXS1) decarboxylates UDP-glcA to produce 
UDP-xylose (UDP-xyl), which is an essential initiating precursor for all chondroitin sulfate 
and heparan sulfate proteoglycans, as well as a precursor for specialized trisaccharides 
needed for surface presentation of proteoglycan receptors such as Notch1. UDP-glc and 
UDP-glcA are the substrate and product of UGDH, respectively. Similarly, UDP-glcA and 
UDP-xyl are the substrate and product of UXS1. Absolute quantification of these nucleotide 
sugars revealed significantly altered profiles in LNCaP 81 relative to LNCaP 33 cells (Fig 
5B). Replotting the ratio of UDP-glcA to UDP-glc provides a measure of the relative flux 
through UGDH, while the ratio of UDP-xyl to UDP-glcA indicates flux through UXS1 (Fig 
5C). From these plots, it was evident that LNCaP 81 had significantly higher levels of UDP-
glcA and >2-fold higher product/substrate ratio for UGDH than LNCaP 33 cells, while the 
UXS1 product/substrate ratio was only ≈30% in LNCaP 81 relative to LNCaP 33.
Higher UDP-glcA in LNCaP 81 cells was not secreted as DHT-glucuronide (Fig 5D) so we 
measured expression of UXS1 and Notch 1 to assess flux through this arm of the pathway. 
UXS1 levels in androgen-depleted and refed cells was modestly higher in LNCaP 81 cells at 
all DHT doses and did not exhibit significant androgen dependence (Fig 5E). Expression of 
the xylose-modified mature proteoglycan Notch 1 was significantly androgen stimulated at 
all doses in LNCaP 33 cells following a short-term androgen depletion (Fig 5F). 
Importantly, overall steady state expression of both the full-length (FL) Notch 1 protein and 
the mature cleaved Notch 1 intracellular/transmembrane domain (NTM) indicative of the 
correctly glycosylated state of the protein was increased ≈5-fold and ≈2-fold, respectively, 
in LNCaP 81 cells (Fig 5G).
To confirm and extend these results, we also profiled metabolites and Notch 1 expression in 
22Rv1 and PC3 cells. The overall responses of 22Rv1 cells were very similar to those of 
LNCaP 81 cells. Specifically, steady state UDP-sugar levels were comparable in magnitude 
and the ratios exhibited the same trends of higher UDP-glcA and lower UDP-xyl (Fig S2A–
S2B). DHT-glucuronide secretion was not detectable in either 22Rv1 or PC3 media, so we 
compared glucuronidation of androstanediol (A-diol), the immediate major product of DHT 
catabolism. A-diol-glucuronide was ≈80–100-fold lower in both lines, relative to LNCaP 33 
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and 81 (Fig S2C). UXS1 expression was not different from LNCaP 33 (Fig S2D), but Notch 
1 NTM and FL were also increased 2-fold and 6-fold, respectively, in 22Rv1 cells (Fig S2E–
S2F). Collectively, results of these analyses show that altered metabolite profiles indicated 
differences in partitioning of nucleotide sugar precursors that underlie altered 
glucuronidation potential of LNCaP 81 and 22Rv1 cells. Such partitioning is consistent with 
prioritized use of nucleotide sugars for the production of secreted proteoglycans by LNCaP 
81 cells, which permits the cells to retain intracellular androgens.
 Stable UGDH knockdown increases basal AR-mediated gene expression and DHT 
glucuronidation
To test the role of UGDH in androgen dependent gene expression, we compared LNCaP 33 
cells clonally selected for shRNA knockdown of UGDH or expression of a non-targeting 
control vector. Knockdown of UGDH led to significant increases in expression of both PSA 
and UGT2B17, with varied impact on AR expression (Fig 6A–6D). As observed in 
LNCaP81 and 22Rv1 cells, UXS1 levels remained largely unchanged (Fig 6E). However, in 
contrast to the profiles of these lines, the expression of cell surface Notch 1 was >50% 
reduced when UGDH was depleted (Fig 6F). Furthermore, DHT-glucuronide (DHT-G) 
content of the cell-conditioned media from the UGDH knockdown lines was ≈4-fold higher 
(Fig 6G), and A-diol-glucuronide was 1.5–2-fold higher (Fig 6H), relative to the control 
lines. These results are consistent with androgen-dependent cells preferentially partitioning 
UDP-glcA precursors to the glucuronidation pathway in conditions during which UDP-glcA 
is limiting, at the expense of proteoglycan production.
A consequence of persistent UDP-glcA deficiency could be exaggerated cellular androgen 
depletion, which could stimulate expression of androgen biosynthetic enzymes. Therefore, 
we examined expression of two representative enzymes, HSD17B3 and HSD3B1, which 
participate in the conversion of androgen precursors such as DHEA, estrogens, and 
cholesterol, into the potent AR ligand DHT. Both enzymes were expressed at detectable 
levels in all cell lines tested, and both were elevated in LNCaP 81 relative to LNCaP 33 (Fig 
7A,7C). HSD17B3 was not affected by UGDH knockdown (Fig 7B), but HSD3B1 was 
reduced ≈50% in UGDH knockdown lines (Fig 7D). Therefore, elevated androgen 
glucuronidation in the absence of UGDH, which would be expected to diminish cellular 
androgen levels, did not act globally to increase enzyme capacity for biosynthesis of 
androgens in LNCaP 33 cells. However, the increased expression of biosynthetic enzymes in 
LNCaP 81 cells would be predicted to increase androgens available for glucuronidation, but 
this was not reflected in glucuronide production (Fig 5D). We further examined the 
expression of the ARv7 splice variant, which lacks the androgen binding domain and has 
been shown to initiate expression of a separate pool of genes from those under control of the 
full length AR. Only 22Rv1 cells expressed detectable levels of ARv7 (Fig S3A), which 
could contribute to the partial constitutive derepression of UGT2B17 in those cells, but does 
not explain the similar outcome in the LNCaP lines and UGDH knockdown sublines. 
Finally, we quantified basal expression of the pioneer transcription factor FoxA1, which is 
required for UGT2B17 expression. However, levels were unchanged in any of the lines, 
except PC3 (Fig S3B). In the latter, the low levels of FoxA1 could partly account for the 
virtually undetectable level of UGT2B17. Collectively, the results suggest altered expression 
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of ARv7, FoxA1, and HSD enzymes are not general underlying factors mediating metabolite 
partitioning, but that metabolite fate priorities are dependent on UGDH expression.
 Discussion
Mechanisms by which prostate tumor cells lose dependence on extracellular androgens 
involve extensive feedback-regulated signaling and crosstalk. Maintaining narrow 
concentration ranges of DHT for optimal AR-mediated gene expression and function 
depends on a balance between exogenous hormone precursors, intracellular synthesis, and 
inactivation. In this study, we compared the function of the androgen-regulated inactivation 
pathway in an isogenic LNCaP model of androgen dependent versus castration resistant 
prostate cancer, to determine the specific role of glucuronidation precursor availability in 
promoting and sustaining androgen dependent gene expression in prostate tumor cells. 
Despite apparent reduced glucuronide output, LNCaP 81 castration resistant tumor cells 
expressed higher levels of UGDH, UGT2B15, and UGT2B17, the component enzymes of 
the glucuronidation pathway. However, the blunted androgen responsive activation of 
UGDH and PSA, and the minimal repression of AR and UGT2B17, were consistent with the 
obvious loss of AR promoter binding and transcriptional activation we also measured. 
Analysis of the UDP-sugar pools and flux through pathways downstream of UDP-glcA 
production revealed that these precursors were channeled instead through proteoglycan and 
glycosaminoglycan biosynthetic pathways, leading to increased surface expression of Notch 
1. Depletion of UDP-glcA by knockdown of UGDH in androgen dependent LNCaP cells 
stimulated glucuronide production and reduced Notch 1. Overall, these results suggest that 
UDP-sugar levels may have a greater impact on androgen sensitivity than previously 
appreciated, by mechanisms independent of protein expression alone.
We previously found that androgen-stimulated UGDH expression increased DHT-
glucuronide content of LNCaP conditioned media in androgen dependent LNCaP 33 cells 
despite strong concurrent suppression of UGT2B15 and UGT2B17 [20], which 
demonstrated that precursor availability could drive glucuronidation with minimal 
glucuronosyltransferase expression. In contrast, we show here that LNCaP 81 cells have 
increased expression of UGDH and UGT, and elevated UDP-glcA precursors, but fail to 
secrete significant DHT-G. This is the more puzzling as the LNCaP 81 cells have been 
reported to have higher levels of intracellular androgen biosynthesis [29], which would be 
expected to contribute further to increased androgen-glucuronide pools. Thus, we sought to 
identify alternative pathways activated concurrently with the loss of androgen dependence. 
Gene expression profiling previously revealed alterations in ErbB2 and Cyclin H in LNCaP 
81, which may promote more rapid cell proliferation independently of androgens [23]. 
Importantly, this report also found elevated expression of PSMA in these cells, which is a 
prostate-specific cell surface chondroitin sulfate proteoglycan. This is consistent with our 
finding that Notch 1 is also upregulated and suggests a global repatterning of UDP-glcA 
fates to preferentially support proteoglycan synthesis.
UDP-glcA is an immediate precursor for UDP-xyl synthesis, which is essential for all 
proteoglycan production. However, UGDH is strongly inhibited by UDP-xyl in vitro [30] 
and this is a potential endogenous regulator of UDP-glcA flux through different pathways. 
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To investigate possible effects of UDP-xyl production on UGDH function, we quantified 
UDP-xyl. Levels are very low relative to the other UDP-sugars (Fig 5B and S2). In 
comparing LNCaP 33 and 81 cells, UDP-xyl appears to be correlated inversely with steady 
state UDP-glcA, which is consistent with the elevated UGDH and UDP-glcA in LNCaP 81 
cells. Similar results were observed in 22Rv1 cells. The significantly lower UDP-xyl levels 
reflect rapid use of UDP-xyl in downstream proteoglycan synthesis, such that its levels do 
not build and inhibit UDP-glcA production, as they do in LNCaP 33. UDP-xylose is 
required for processing of Notch 1 and presentation at the plasma membrane so fluxes in 
UDP-xyl levels would be predicted to affect both full length and processed Notch 1 levels 
[31], as we observed (Fig 5G and S2). Since large amounts of UDP-glcA are also required 
for high level proteoglycan synthesis, which occurs in the Golgi apparatus, while DHT-
glucuronide formation is catalyzed in the ER, the UDP-glcA may be preferentially delivered 
to the Golgi, thereby restricting its availability for androgen glucuronidation in LNCaP 81 
and 22Rv1 cells.
We also found LNCaP 81 cells synthesize ≈2-fold more hyaluronan than LNCaP 33 cells 
[20]. This is a third alternative limiting factor for UDP-glcA availability in LNCaP 81 cells. 
However, we have shown that hyaluronan production suppresses cell proliferation, which is 
not compatible with the selected rapidly proliferating phenotype of the LNCaP 81 cells. 
Nonetheless, it is important to consider that prioritizing UDP-glcA to elevating proteoglycan 
production also requires sufficient nutrient availability to support significantly increased 
protein synthesis. It may be for this reason that we saw LNCaP 33 and 81 cells had similar 
rates of Notch 1 surface expression in 1% serum containing media following androgen 
depletion (Fig 5F) while the steady state Notch 1 levels in standard 10% serum containing 
media were higher in the LNCaP 81 cells. Overall, these results suggest the pathway favored 
by prostate tumor cells selected to avoid dependence on androgens is proteoglycan 
synthesis, because it competes with growth-slowing processes like hyaluronan production 
and androgen glucuronidation. This is further supported by the observation that UGDH 
expression is elevated in cell lines modeling CRPC, and its knockdown reprioritizes use of 
the limited UDP-glcA for glucuronidation, significantly diminishing proteoglycan synthesis.
While it is reasonable to propose that repatterned metabolite use is a driver of prostate tumor 
cell loss of androgen dependence, other possible functional changes cannot be ruled out. Our 
analysis of AR expression showed no evidence of altered splice variant expression between 
LNCaP 33 and 81 cells (Fig 3 and S3), so we do not think ligand-independent AR function 
is the primary factor in the blunted responses we observed in expression of PSA and 
suppression of UGT (Fig 1 and S1). The AR has also been shown to undergo multiple post-
translational modifications that modulate its subcellular localization and its association with 
transcriptional coregulation complexes [32, 9]. We did not examine or quantify these 
modifications so it is possible that androgen-independent gene expression changes occur by 
this mechanism. An additional component of androgen elimination is the organic anion 
transport protein family (OATP), also known as solute carrier proteins denoted SLCO, which 
are the transporters by which androgen conjugates leave and enter the cell. Altered 
expression of specific members of this transporter family has been correlated with castration 
resistant and/or metastatic prostate cancer progression [33–35]. Thus, the reduced secretion 
of DHT-G could occur as a result of such changes, which would be expected to limit 
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production of androgen-glucuronides and prevent use of UDP-glcA in this arm of the 
pathway.
Androgen glucuronidation enzymes have been implicated in prostate cancer risk, metastasis, 
and response to anti-androgen therapy in clinical and mechanistic studies [36, 37, 17, 16, 14, 
13, 18]. Here, we found an association between dampened AR-mediated gene expression 
and increased glucuronidation potential as measured by UDP-glcA precursor availability and 
expression of enzymes in the pathway, which are hallmarks in loss of cellular androgen 
responsiveness. We propose a novel mechanism by which cellular metabolite flux regulates 
androgen dependence through partitioning of glucuronidation precursors. The knockdown of 
UGDH and consequent perturbation of cellular UDP-sugar metabolites yielded an overall 
phenotype that may be more responsive to androgen deprivation. Features of the stable 
UGDH knockdown included increased androgen elimination, decreased proteoglycan 
production, and reduced HSD3B1 expression. In prostate tumor cells, the biosynthesis of 
testosterone and DHT from the alternative circulating precursor DHEA-S is directly 
controlled by HSD3B1. Thus, the net outcome of UGDH inhibition would be to deplete all 
intracellular androgens while preventing the proteoglycan “escape route”. It will be 
interesting to determine whether loss of UGDH in castration resistant tumor cells can 
reverse metabolite partitioning and restore androgen sensitivity. These insights may provide 
new diagnostic tools or therapeutic targets to predict castration resistant recurrence.
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Fig. 1. Castration resistant prostate tumor cells exhibit blunted ligand-dependent AR responses, 
with higher levels of glucuronidation enzymes relative to androgen sensitive controls
LNCaP 33 and LNCaP 81 cells were cultured in androgen depleted media for 48 h, followed 
by 48 h of treatment with the indicated doses of DHT. Total cell lysates were analyzed in 
triplicate by immunoblots probed for the indicated proteins: A) UGDH; B) PSA; C) AR; D) 
UGT2B17. Densitometric quantification was normalized to tubulin and plotted as mean ± 
SEM of fold changes relative to the LNCaP 33 0 nM treatment. * p<0.05 relative to LNCaP 
33, 0 nM DHT; ‡ p<0.05 for LNCaP 81 relative to LNCaP 33 at the indicated DHT 
treatment.
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Fig. 2. Re-expression of AR-activated genes UGDH and PSA is dose dependent following 
prolonged androgen depletion
LNCaP 33 and 81 cells were selected for ten days in the indicated DHT concentrations. 
Prior to harvest, media were removed and replaced with media containing vehicle or 10 nM 
DHT for 24 h. (A) Equivalent amounts of protein were immunoblotted for UGDH and 
tubulin. UGDH expression was quantified, normalized to tubulin and plotted as the ratio of 
24 h DHT-treated versus vehicle-treated expression to illustrate stimulated expression. Mean 
± SEM is plotted; * p<0.05 relative to LNCaP 33 at 10 nM DHT; ‡ p<0.05 for LNCaP 81 
relative to LNCaP 33 at the indicated DHT treatment. (B) Blots in (A) were reprobed for 
PSA (34 kDa) and AR (102 kDa).
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Fig. 3. Strong androgen dependent repression of UGT enzymes is maintained in androgen 
sensitive LNCaP 33 cells but lost in castration resistant LNCaP 81 cells
LNCaP 33 and 81 cells were selected for ten days in the absence of DHT (A) or in the 
indicated DHT concentrations (B and C). Prior to harvest, media were removed and replaced 
with media containing vehicle or 10 nM DHT for 24 h. Total RNA was extracted and 
analyzed for UGT2B15 (B) and UGT2B17 (C) expression by qRT-PCR. Mean ± SEM of 
triplicate assays is plotted. In (A), expression was compared in cells cultured only in 
androgen-depleted media for the indicated times, without DHT stimulation; * p<0.05 for 10 
days relative to 3 days. For panels B and C, * p<0.05, DHT deficient selection relative to 10 
nM selection; ‡ p<0.05 for vehicle vs. DHT in each selection.
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Fig. 4. Prolonged androgen depletion dampens ligand-dependent function of the AR in LNCaP 
33 and 81 cells
Cells were selected in 0, 0.1, 1, or 10 nM DHT for 48 h or for 10 days. Selected cells were 
then treated with vehicle or 10 nM DHT prior to assay. (A) Genomic DNA was analyzed by 
anti-AR ChIP. AR occupancy of the PSA promoter was quantified by qPCR in technical 
duplicates and plotted as % input (fraction of total immunoprecipitated DNA amplified by 
the gene-specific primers). Data shown represent mean ± SEM for one of three assays 
replicated with identical trends. (B) Following selection, cells were co-transfected with 
PSA-Luc and Renilla reporter constructs and subsequently treated with vehicle or 10 nM 
DHT for another 24 h before assaying luciferase activity. Mean ± SD of normalized activity 
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measured in triplicate is plotted. * p<0.05 for DHT restimulated relative to unstimulated at 0 
nM.
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Fig. 5. Metabolite analysis of glucuronidation pathway components
A) Schematic of the glucuronidation pathway and its alternatives. B) UDP-sugar content was 
quantified by LC-MS in whole lysates from LNCaP 33 and LNCaP 81 cells cultured in 
standard serum-containing media. Mean ± SD is plotted. C) The ratios of UDP-glucuronate 
(UDP-glcA) to UDP-glucose (UDP-glc), and UDP-xylose (UDP-xyl) to UDP-glcA were 
calculated from mean values in (B) to illustrate steady state intracellular flux through UGDH 
and UXS1, respectively. Note that the scale for UDP-xyl/UDP-glcA is ×10−3. D) DHT-G 
secretion was quantified from conditioned media of each cell line and plotted as mean ± SD. 
E and F) LNCaP 33 and LNCaP 81 cells were cultured in androgen depleted media for 48 
hours, followed by 48 hours of treatment with the indicated doses of DHT. Total cell lysates 
were analyzed in triplicate by immunoblots probed for UXS1 (E) or Notch 1 (F). G) Lysates 
from cells cultured in standard media were analyzed by immunoblot for Notch 1. NTM 
indicates quantification of the ≈120 kDa intracellular and transmembrane domain of Notch 
1; FL denotes the ≈272 kDa full length Notch 1 protein. In panels E–G, densitometric 
quantification was normalized to tubulin and mean ± SEM is plotted. * p<0.05 relative to 
LNCaP 33, 0 nM DHT; ‡ p<0.05 for LNCaP 81 relative to LNCaP 33 at the indicated DHT 
treatment.
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Fig. 6. Stable UGDH knockdown increases basal AR-mediated gene expression and androgen 
glucuronidation, while diminishing Notch1 proteoglycan expression
Two individual clones of LNCaP 33 cells selected for stable UGDH-targeted shRNA 
knockdown or non-targeted shRNA controls were grown in standard steroid-replete media. 
Whole cell lysates were analyzed by western blot for (A) UGDH, (B) PSA, (C) AR, (D) 
UGT2B17, (E) UXS1, or (F) the intracellular and transmembrane domain of Notch1 (NTM). 
Expression was normalized to tubulin and plotted as mean ± SEM for three biological 
replicates of each clone. (G) DHT-G or (H) Adiol-G secretion was quantified from 
conditioned media of each clone and plotted as mean ± SD. In all panels, * p<0.05 relative 
to values for C1.
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Fig. 7. UGDH knockdown reduces HSD3B1
LNCaP 33, 81, 22Rv1, and PC3 cell lines (A and C) or LNCaP 33 control and UGDH 
knockdown clones (B and D) were grown in standard steroid-replete media. Total cell 
lysates were normalized by protein content and analyzed in triplicate by immunoblots 
probed for HSD17B3 (A and B) or HSD3B1 (C and D). Densitometric quantification was 
normalized to tubulin and plotted as mean ± SEM of fold changes relative to LNCaP 33 or 
C1. * p<0.05 relative to LNCaP 33; ‡ p<0.05 relative to C1.
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